Open access
Oct 2026
A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine resistant metastatic breast cancer.
BACKGROUND Patients with endocrine-resistant hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and function; its inhibition has been proposed as a strategy to overcome endocrine resi...
A. Grinshpun, A. Waks, Jing-Xin Fu et al.
· The Oncologist · 0 citations